Movatterモバイル変換

[0]ホーム
URL:

Barati et al., 2006 - Google Patents

GDNF gene delivery via the p75NTR receptor rescues injured motor neurons

Barati et al., 2006

ViewPDF
Document ID
3844371409107011303
Author
Barati S
Hurtado P
Zhang S
Tinsley R
Ferguson I
Rush R
Publication year
Publication venue
Experimental neurology

External Links

Snippet

The retrograde axonal transport mechanism of motor neurons has been exploited to deliver the gene encoding Glial cell line-derived neurotrophic factor (GDNF) into the central nervous system to provide trophic support following injury. A nonviral gene delivery system …
Continue reading atwww.academia.edu (PDF) (other versions)

Classifications

The classifications are assigned by a computer and are not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

PublicationPublication DateTitle
Barati et al.GDNF gene delivery via the p75NTR receptor rescues injured motor neurons
Park et al.Neuron‐specific delivery of nucleic acids mediated by Tet1‐modified poly (ethylenimine)
AU765436B2 (en)Compositions and methods for delivery of agents for altering neuronal growth, regeneration, and survival
EP2892567B1 (en)Parkinson's disease treatment by bdnf-flag gene transfer through neurotensin polyplex to nigral dopamine neurons
Baba et al.Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles
Storrie et al.Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering
Choi-Lundberg et al.Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor
Hernandez-Chan et al.Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson’s disease
Berry et al.Sustained effects of gene-activated matrices after CNS injury
Conley et al.Nanoparticles for retinal gene therapy
US20210024907A1 (en)Nucleic acid-based therapeutics
Péan et al.Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons
Lu et al.Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport
Yurek et al.Long-term transgene expression in the central nervous system using DNA nanoparticles
US20090280058A1 (en)Delivery Of Double-Stranded RNA Into The Central Nervous System
DE60008915T2 (en) CONSTRUCTS FOR THE ADMINISTRATION OF THERAPEUTIC ACTIVE SUBSTANCES TO NEURON CELLS
JP2010150278A (en)Method of alleviating cancer symptom
Chung et al.Polybutylcyanoacrylate nanoparticles for delivering hormone response element-conjugated neurotrophin-3 to the brain of intracerebral hemorrhagic rats
Gwak et al.Multifunctional nanoparticles for gene delivery and spinal cord injury
Rebelo et al.Efficient spatially targeted gene editing using a near-infrared activatable protein-conjugated nanoparticle for brain applications
Reyes-Corona et al.Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion
Yao et al.Non-viral gene therapy for spinal cord regeneration
WO1999053961A1 (en)Peptides for efficient gene transfer
Rhim et al.Targeted delivery of growth factors in ischemic stroke animal models
CN114933657B (en) Nerve growth factor mutant recombinant protein and its application
[8]ページ先頭
©2009-2025 Movatter.jp